Bulevirtide
Also known as: BLV, Bulevirtide, Hepcludex, MYR110, Myrcludex B
Source Bulevirtide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Bulevirtide (BLV, Hepcludex) is a first‑in‑class lipopeptide that blocks hepatitis D virus (HDV) entry into liver cells. It is approved in the European Union for chronic hepatitis D (CHD) in adults with compensated liver disease and is administered by subcutaneous injection. Clinical trials have examined both monotherapy and combination with pegylated interferon‑alpha, showing virologic and biochemical improvements over 48‑ to 96‑week treatment periods.
Mechanism of Action
Bulevirtide binds to the sodium‑taurocholate cotransporting polypeptide (NTCP) on hepatocytes, the cellular receptor that HDV (and HBV) use to enter liver cells. By occupying this entry site, the drug prevents new HDV particles from infecting hepatocytes, thereby limiting viral spread and downstream liver injury. The action is specific to viral entry and does not affect HBV replication directly.
What the Research Shows
Phase 3 data (MYR301) showed that 2 mg or 10 mg daily bulevirtide produced a combined virologic‑biochemical response in 45‑48% of patients at week 48, versus 2% with delayed treatment, and ALT normalization in over half of treated patients. A 96‑week extension confirmed maintained or improved responses, with similar efficacy at both doses and notable gains among early non‑responders. A phase 2b study found that 10 mg bulevirtide plus pegylated interferon‑alpha achieved undetectable HDV RNA in 46% of patients 24 weeks after treatment, markedly higher than bulevirtide alone (12%). Safety across studies was favorable, with most adverse events mild to moderate.
Reported Benefits
Clinical trials demonstrate that bulevirtide can reduce HDV RNA levels and normalize liver enzymes in a substantial proportion of patients, offering a disease‑specific option where previous therapies were limited. Longer‑term treatment appears to deepen virologic responses and improve liver stiffness, and combination with pegylated interferon further enhances RNA clearance. The drug is generally well tolerated, enabling chronic administration.
Limitations of the Evidence
Even with optimal dosing, only about half of patients achieve the combined response, and complete viral eradication is uncommon. Loss of hepatitis B surface antigen has not been observed, indicating persistent HBV infection. Data are limited to trial populations with compensated disease; efficacy in decompensated cirrhosis or diverse real‑world settings remains uncertain. Direct head‑to‑head comparisons with other emerging agents are lacking.
Safety Considerations
Adverse events are mostly grade 1‑2. Monotherapy reports include headache, pruritus, fatigue, eosinophilia, injection‑site reactions, abdominal pain, arthralgia, and dose‑related bile‑acid elevations. When combined with pegylated interferon, hematologic cytopenias (leukopenia, neutropenia, thrombocytopenia) are more frequent. No serious drug‑related adverse events have been reported in the trials, but monitoring of liver function, bile acids, and blood counts is advisable.
How It Is Administered
Bulevirtide is given as a daily subcutaneous injection. Clinical studies have used fixed doses of 2 mg or 10 mg. In combination regimens, pegylated interferon‑alpha is administered once weekly. Formulations are supplied as sterile solution for injection; dosing adjustments are not currently recommended beyond the studied ranges.
Routes of Administration
Goals & Uses
- HBV entry inhibitionViral InfectionModerate
- ALT normalization in chronic HDVHepatic Inflammation ReductionHigh
- Suppression of HDV RNAAntiviral EfficacyHigh
- Chronic hepatitis D infectionViral InfectionHigh
- Combination therapy with pegylated interferon-alphaCombination Antiviral StrategyModerate
- Prevention of HBV/HDV co-entryAntiviral MechanismHigh
- Reduction of liver fibrosis progressionHepatoprotectionModerate
Contraindications
- Severe hepatic impairment (Child‑Pugh C)Liver DiseaseModerate
- Concurrent use of NTCP-inhibiting drugs (e.g., cyclosporine, certain statins)Drug InteractionModerate
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Hypersensitivity to bulevirtide or excipientsAllergy/immunologicHigh
- Decompensated liver diseaseHepatic ImpairmentHigh
Adverse Effects
- Pruritus (systemic)DermatologicCommon
- HBV DNA or surface antigen increase upon discontinuationVirologic ReboundUncommon
- Injection site reactionsLocalCommon
- HeadacheNeurologicCommonPain in the head or upper neck
- Elevated ALT/ASTHepaticUncommon
- FatigueGeneralCommonLow energy or tiredness
- Elevated bile acid levels (hypercholanemia)MetabolicCommon
- Injection site reactionLocalCommonRedness, swelling, itching, bruising, or pain at the injection site
Drug Interactions
- RifampicinModerate
- CyclosporineHigh
- Tenofovir alafenamide / nucleos(t)ide analogues for HBVLow
- Pegylated interferon alfa‑2aLow
- Statins (NTCP substrates, e.g., rosuvastatin)Moderate
- Nucleos(t)ide analogues (e.g., tenofovir)Low
Population Constraints
- PregnancyReproductive SafetyRelative
- Severe renal impairmentOrgan ImpairmentRelative
- Pediatric patients (<18 years)AgeAbsolute
- Decompensated cirrhosis (Child-Pugh B/C)Hepatic ImpairmentAbsolute
- Pregnant womenReproductiveAbsolute
- BreastfeedingReproductiveRelative
- Children <12 yearsAgeAbsolute
Regulatory Status
- European UnionApprovedApproved: Chronic hepatitis D infectionMarketed as Hepcludex.
- United StatesInvestigationalUnder FDA review; not yet approved.
- United KingdomApprovedApproved: Chronic hepatitis D infectionApproved following EU pathway.
Approved in the European Union (2020) for chronic hepatitis D; under FDA review in the United States and not yet approved there.
Evidence & Sources
- Journal ArticleModerateAsselah T, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModerateWedemeyer H, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateKang C, Syed YY2020-01-01T00:00:00.000000Z
- Journal ArticleModerateUrban S, Neumann-Haefelin C, Lampertico P2021-01-01T00:00:00.000000Z
- Journal ArticleModerateWedemeyer H, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModerateNegro F, Lok AS2023-01-01T00:00:00.000000Z
Frequently Asked Questions
What condition does bulevirtide treat?
Bulevirtide is approved in the EU for chronic hepatitis D infection in adults with compensated liver disease. It targets the entry step of HDV into hepatocytes, addressing a disease that previously had limited therapeutic options.
How is bulevirtide given and how often?
The drug is administered by subcutaneous injection once daily. Clinical trials have evaluated fixed doses of 2 mg and 10 mg. When used with pegylated interferon‑alpha, the interferon is given once weekly.
Can bulevirtide cure hepatitis D?
Trials show bulevirtide can suppress HDV RNA and normalize liver enzymes in many patients, but complete viral eradication is uncommon. It provides significant disease control rather than a definitive cure.
What are the most common side effects?
Typical mild‑to‑moderate effects include headache, itching, fatigue, injection‑site reactions, and elevated bile acids. When combined with pegylated interferon, blood‑cell count reductions such as leukopenia and neutropenia occur more often.
Is bulevirtide safe for long‑term use?
Long‑term data up to 96 weeks show the drug remains well tolerated, with no serious adverse events attributed to bulevirtide. Ongoing monitoring of liver tests, bile acids, and blood counts is recommended during extended therapy.
What is Bulevirtide?
Bulevirtide (BLV, Hepcludex) is a first‑in‑class lipopeptide that blocks hepatitis D virus (HDV) entry into liver cells. It is approved in the European Union for chronic hepatitis D (CHD) in adults with compensated liver disease and is administered by subcutaneous injection. Clinical trials have examined both monotherapy and combination with pegylated interferon‑alpha, showing virologic and biochemical improvements over 48‑ to 96‑week treatment periods.
What is Bulevirtide used for?
Bulevirtide is educationally associated with: HBV entry inhibition, ALT normalization in chronic HDV, Suppression of HDV RNA, Chronic hepatitis D infection, Combination therapy with pegylated interferon-alpha, Prevention of HBV/HDV co-entry, Reduction of liver fibrosis progression. Educational only — not medical advice.
How is Bulevirtide administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Bulevirtide?
Reported adverse effects include: Pruritus (systemic), HBV DNA or surface antigen increase upon discontinuation, Injection site reactions, Headache, Elevated ALT/AST, Fatigue, Elevated bile acid levels (hypercholanemia), Injection site reaction. This list is not exhaustive — consult a qualified clinician.
Who should avoid Bulevirtide?
Recorded contraindications: Severe hepatic impairment (Child‑Pugh C), Concurrent use of NTCP-inhibiting drugs (e.g., cyclosporine, certain statins), Pregnancy, Hypersensitivity to bulevirtide or excipients, Decompensated liver disease. Consult a qualified clinician before use.